Key facts
- This page summarizes J. Kevin Buchi's Form 4 filing for Benitec Biopharma Inc. (BNTC).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Mar 2025, 14:20.
J. Kevin Buchi - 27 Feb 2025 Form 4 Insider Report for Benitec Biopharma Inc. (BNTC)
- Reporting relationship
- Director
- Issuer ticker
- BNTC
- Reported as of
- 27 Feb 2025
- Net transaction value
- +$199,998
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2025, 14:20:29 UTC
- Prior SEC filing
- 11 Dec 2024
- Next SEC filing
- 12 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ J. Kevin Buchi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
J. Kevin Buchi filed Form 4 for Benitec Biopharma Inc. (BNTC) on 03 Mar 2025.
Change
- Previous filing in this sequence was filed on 11 Dec 2024.
- Current net transaction value: +$199,998.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BNTC
transaction
Common Stock
Options Exercise
- Transaction value
- $199,998
- Shares
- +51,813
- Change %
- +99%
- Price
- $3.86
- Shares after
- 103,910
- Date
- 27 Feb 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BNTC
transaction
Derivative
Common Warrants (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -51,813
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 27 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 51,813
- Exercise price
- $3.86
* marks a reported price that did not pass the local price check.